Clinical Trial Update: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Sunvozertinib plus Anlotinib as first-line therapy for EGFR-sensitizing mutations with co-mutations in advanced non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• Sunvozertinib (Sunvozertinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: RECRUITING